Literature DB >> 22010206

MRSA: the first half century.

Robert C Moellering1.   

Abstract

Fifty years ago methicillin-resistant Staphylococcus aureus (MRSA) first revealed themselves to the medical community, having been described in a landmark article published in the British Medical Journal. Among other things, their discovery set off a major response from the scientific and medical professions to control or even eliminate them as major human pathogens. Despite these efforts, however, MRSA have spread throughout the world and a half century after they burst upon the scene they continue to pose major challenges to research scientists and clinicians alike. In a very real sense, this year marks the 'birthday' of a remarkably successful pathogen. The major reasons for the ability of MRSA to prosper and cause disease in settings inimical to its survival form the basis of this article.

Entities:  

Mesh:

Year:  2011        PMID: 22010206     DOI: 10.1093/jac/dkr437

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  56 in total

1.  Antibiotic-loaded nanoparticles targeted to the site of infection enhance antibacterial efficacy.

Authors:  Sazid Hussain; Jinmyoung Joo; Jinyoung Kang; Byungji Kim; Gary B Braun; Zhi-Gang She; Dokyoung Kim; Aman P Mann; Tarmo Mölder; Tambet Teesalu; Santina Carnazza; Salvatore Guglielmino; Michael J Sailor; Erkki Ruoslahti
Journal:  Nat Biomed Eng       Date:  2018-01-22       Impact factor: 25.671

2.  Biofilm formation on tympanostomy tubes depends on methicillin-resistant Staphylococcus aureus genetic lineage.

Authors:  Ana Jotić; Dragana D Božić; Jovica Milovanović; Bojan Pavlović; Snežana Ješić; Mijomir Pelemiš; Marko Novaković; Ivana Ćirković
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-03-22       Impact factor: 2.503

3.  Ten old antibiotics that will never disappear.

Authors:  Matteo Bassetti; Matthew E Falagas; Marin Kollef
Journal:  Intensive Care Med       Date:  2015-02-25       Impact factor: 17.440

4.  TXA709, an FtsZ-Targeting Benzamide Prodrug with Improved Pharmacokinetics and Enhanced In Vivo Efficacy against Methicillin-Resistant Staphylococcus aureus.

Authors:  Malvika Kaul; Lilly Mark; Yongzheng Zhang; Ajit K Parhi; Yi Lisa Lyu; Joan Pawlak; Stephanie Saravolatz; Louis D Saravolatz; Melvin P Weinstein; Edmond J LaVoie; Daniel S Pilch
Journal:  Antimicrob Agents Chemother       Date:  2015-06-01       Impact factor: 5.191

5.  Exposing a chink in the armor of methicillin-resistant Staphylococcus aureus.

Authors:  Iain C Sutcliffe
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-01       Impact factor: 11.205

6.  Population-based study of the increased incidence of skin and soft tissue infections and associated antimicrobial use.

Authors:  Fawziah Marra; David M Patrick; Mei Chong; Rachel McKay; Linda Hoang; William R Bowie
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

7.  Effects of Phage Endolysin SAL200 Combined with Antibiotics on Staphylococcus aureus Infection.

Authors:  Wan Beom Park; Hong Bin Kim; Nak-Hyun Kim; Jeong Eun Cho; Yoon Jeong Choi; Su Jin Choi; Soo Youn Jun; Chang Kyung Kang; Kyoung-Ho Song; Pyoeng Gyun Choe; Ji-Hwan Bang; Eu Suk Kim; Sang Won Park; Nam-Joong Kim; Myoung-Don Oh
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

8.  Staphylococcal SCCmec elements encode an active MCM-like helicase and thus may be replicative.

Authors:  Ignacio Mir-Sanchis; Christina A Roman; Agnieszka Misiura; Ying Z Pigli; Susan Boyle-Vavra; Phoebe A Rice
Journal:  Nat Struct Mol Biol       Date:  2016-08-29       Impact factor: 15.369

9.  High-level expression, purification, and characterization of Staphylococcus aureus dihydroorotase (PyrC) as a cleavable His-SUMO fusion.

Authors:  Lena Truong; Kirk E Hevener; Amy J Rice; Kavankumar Patel; Michael E Johnson; Hyun Lee
Journal:  Protein Expr Purif       Date:  2012-12-13       Impact factor: 1.650

10.  In Vivo Pharmacodynamic Evaluation of an FtsZ Inhibitor, TXA-709, and Its Active Metabolite, TXA-707, in a Murine Neutropenic Thigh Infection Model.

Authors:  Alexander J Lepak; Ajit Parhi; Michaela Madison; Karen Marchillo; Jamie VanHecker; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2015-08-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.